Ani Pharmaceuticals (ANIP) Goodwill & Intangibles (2012 - 2026)

Ani Pharmaceuticals has reported Goodwill & Intangibles for 15 years, with the latest figure at $529.6 million in Q1 2026.

• Quarterly Goodwill & Intangibles fell 11.6% year-over-year to $529.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $529.6 million (down 11.6% YoY) and the FY2025 annual result came in at $542.0 million, down 9.94% from the prior year.
• Goodwill & Intangibles slipped to $529.6 million in Q1 2026 per ANIP's latest filing, from $542.0 million in the prior quarter.
• Over five years, Goodwill & Intangibles peaked at $630.3 million in Q3 2024 and troughed at $32.5 million in Q2 2023.
• A 5-year average of $349.5 million and a median of $292.5 million in 2022 frame the typical range for Goodwill & Intangibles.
• The sharpest annual moves came in 2023 and 2024: Goodwill & Intangibles slumped 89.08% in 2023, then surged 549.73% in 2024.
• Over 5 years, Goodwill & Intangibles stood at $279.8 million in 2022, then fell by 15.23% to $237.2 million in 2023, then jumped by 153.69% to $601.8 million in 2024, then dropped by 9.94% to $542.0 million in 2025, then decreased by 2.28% to $529.6 million in 2026.
• According to Business Quant data, Goodwill & Intangibles over the past three periods registered $529.6 million, $542.0 million, and $562.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.